Orforglipron
Fat LossFDA-approved oral small-molecule GLP-1 agonistEstablished
FDA-approved April 1, 2026 (Foundayo). Once-daily non-peptide oral GLP-1 receptor agonist for chronic weight management without food or water timing restrictions.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mg
- Administration Route
- Oral
- Frequency
- Once daily
- Last updated
- Aug 23, 2026
- Targets
- GLP-1 receptor
Overview
FDA-approved April 1, 2026 (Foundayo). Once-daily non-peptide oral GLP-1 receptor agonist for chronic weight management without food or water timing restrictions.
Protocol
- Dosage Range
- Once-daily oral titration per Foundayo label
- Frequency
- Once daily
- Cycle
- Long-term as prescribed
- Administration Route
- Oral
- Reconstitution Guide
- Tablet — no reconstitution
- Timing Notes
- Educational catalog only — not medical advice
Science
Mechanism of Action
Small-molecule GLP-1R agonist that can be taken orally any time of day. ATTAIN Phase 3 supported weight-management approval.
Origin
Discovered by Chugai; developed by Lilly.
Targets
GLP-1 receptor
Benefits
Oral GLP-1 without peptide injectionNo food/water window like Rybelsus
Potential Side Effects
Side Effects
- GI class effects
References
- Lilly Foundayo approval (2026-04-01)External reference